Evaluating the effectiveness of 2LVERU® for treating warts
Official title: Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.
Run by Labo'Life · NCT03977753 · Data updated 2026-11-12
This study is testing if a new treatment called 2LVERU® can help people aged 3 and older get rid of different types of warts better than a placebo.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 3 Years and up |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | Labo'Life Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 6 sites (Bouge and 5 other locations) |
| Status | Recruiting |
| Started | February 17, 2020 |
| Main results expected | December 16, 2028 |
| Study ends | February 16, 2029 |
| Registry record updated | August 31, 2026 |
| Trial ID | NCT03977753 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 3 years and older with common, flat, or plantar warts.
✕Probably not a fit
Patients who have received any curative wart treatment in the previous two months or those with immunosuppressive conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess the efficacy of 2LVERU® and 2LVERU® JUNIOR in treating common warts, flat warts, and plantar warts compared to a placebo. The study will involve patients aged 3 years and older who present with these types of warts during a visit to their healthcare provider. Participants will be randomly assigned to receive either the treatment or a placebo for six months, followed by a three-month follow-up period to evaluate wart disappearance and recurrence. The primary outcome will be the comparison of wart disappearance rates at the end of treatment.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective option for patients suffering from warts, potentially leading to complete eradication of the lesions.
How similar studies have gone: While conventional treatments exist, this specific approach using 2LVERU® has not been extensively tested in similar studies, making it a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients, male or female, aged 3 years and older, * Patients with common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana), * Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study, * Signature of the Informed Consent Form by the patient (and/or parents if necessary). Exclusion Criteria: * Patients who have received any curative warts treatment in the previous 2 months prior to the study, * Patients who have received any homeopathic treatment in the previous 2 months prior to the study, * Patients under immunosuppressive treatment, * Patients having received immunotherapy or micro-immunotherapy during the last 6 months, * Patients with known lactose intolerance, * Pregnant or breastfeeding women, * Patients who participated in a clinical study in the previous 2-months period, * Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study, * Patients with severe immunodeficiency disease requiring long term treatment (\*) or patients under chemotherapy or radiotherapy, * Patients under listed homeopathic or phytotherapy treatment (see protocol), * Patients addicted to or using recreational drugs, * Patient under guardianship and/or curators, (\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.
Where it's running
-
Clinique Saint-Luc (Bouge)
Bouge, Belgium Recruiting -
Private Practice
Ghent, Belgium Recruiting -
Private Practice
Saint-Symphorien, Belgium Recruiting -
Private Practice
Seneffe, Belgium Recruiting -
Private Practice
Wavre, Belgium Recruiting -
Private Practice
Oisquercq, Belgium Terminated
Study contacts
- Study coordinator: Charlotte Bolle
- Email: charlotte.bolle@labolife.com
- Phone: (0)497 49 13 74
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Wart injections: vitamin D3 versus acyclovir
This test will try injecting either vitamin D3 or acyclovir into skin warts to see which better clears warts in people aged 12 and older.
-
Evaluating 2LEBV® and 2LXFS® for fatigue in Epstein-Barr Virus patients
This study is testing two new medications to see if they can help people aged 12 and older who have been feeling very tired due to Epstein-Barr Virus infections.
-
Treatment for clearing genital HR-HPV infections using 2LPAPI®
This study is testing if a new immune treatment called 2LPAPI® can help women aged 25 to 45 clear high-risk HPV infections more effectively than a placebo.
-
Evaluating 2LHERP® for treating recurrent orofacial herpes infections
This study is testing if a new treatment called 2LHERP® can help adults with frequent orofacial herpes infections have fewer outbreaks over a year.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.